

WHAT IS CLAIMED IS:

1           1.    A polypeptide comprising a fusion of a  
2   transcription factor, the transcription factor comprising a  
3   DNA binding domain, and a retinoblastoma (RB) polypeptide, the  
4   RB polypeptide comprising a growth suppression domain.

1           2.    A nucleic acid encoding the fusion polypeptide  
2   of claim 1.

1           3.    The nucleic acid of claim 2, wherein the  
2   nucleic acid is inserted in an adenovirus vector.

1           4.    The polypeptide of claim 1, wherein the  
2   transcription factor is E2F.

1           5.    The polypeptide of claim 4, wherein the cyclin  
2   A binding domain of the E2F is deleted or nonfunctional.

1           6.    The polypeptide of claim 1, wherein the  
2   retinoblastoma polypeptide is RB56.

1           7.    The polypeptide of claim 1, wherein the  
2   retinoblastoma polypeptide is wild type RB.

1           8.    The polypeptide of claim 1, wherein the  
2   retinoblastoma polypeptide comprises from about amino acid  
3   residue 379 to about amino acid residue 928 of pRB.

1           9.    The polypeptide of claim 1, wherein the  
2   retinoblastoma polypeptide comprises at least one substitution  
3   of amino acid residues selected from the group consisting of  
4   2, 608, 612, 788, 807, and 811 of pRB.

1           10.   The polypeptide of claim 5, wherein the E2F  
2   comprises about amino acid residues 95 to about 286.

1  
2

- 1
- 2
- 3
- 4

- 1
- 2
- 3
- 4
- 5

1  
2  
3

12

—  
—  
—  
—  
—  
—  
—  
—

1                    21. The method of claim 16, wherein the RB is wild  
2       type RB56.

1                    23. The method of claim 16, wherein the RB  
2 comprises at least one substitution of amino acid residues  
3 selected from the group consisting of 2, 608, 612, 788, 807,  
4 and 811.

1            25. The method of claim 18, wherein the E2F  
2 comprises about amino acid residues 95 to about 194.

1                    27. The method of claim 18, wherein the E2F -RB  
2                    fusion polypeptide is expressed under the control of a tissue-  
3                    specific promoter.

1                    29. The method of claim 16, wherein the  
2    hyperproliferative disorder is cancer.

1            30. The method of claim 29, wherein the cancer is  
2 bladder cancer.

1  
21  
2

- 1
- 2
- 3

1  
21  
2

12

ADD  
A2

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100